Become A Wiser, More Profitable Investor

Biotech investments surged in Q1 2024, especially in ADCs and radiopharmaceuticals

health

Q1 2024 witnessed a substantial increase in biotech venture funding, with a significant focus on antibody-drug conjugates (ADCs) and radiopharmaceuticals. ADCs saw a fivefold increase in investment from $98 million in Q4 2023 to $568 million in Q1 2024. The largest venture financing deal was Tubulis' $139 million Series B2 funding for its ADC lead candidates. Radiopharmaceuticals also experienced over a 330% surge in venture capital investment. Companies like AstraZeneca and Merck have been actively expanding their biopharmaceutical portfolios through acquisitions and partnerships. For instance, AstraZeneca's $2.4 billion takeover of Fusion Pharmaceuticals and Merck's $3 billion deal in eye disease biotech exemplify ongoing consolidation trends in the biotech sector [21][25][23].

Helium Trades     Jun 01, 2024